Latest Medical Devices News

Universal Biosensors will lift its trading suspension following the announcement of a non-binding term sheet for a senior secured loan facility, signaling a potential boost to its financial position.

Universal Biosensors has signed a non-binding term sheet for an A$8.5 million senior secured loan with Viburnum Funds, alongside plans for an equity raising. The move comes with governance shifts, including a director resignation to avoid conflicts.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

Adherium Limited has announced an accelerated non-renounceable entitlement offer to raise approximately A$4 million, issuing new shares and options to fund expansion and product development. The offer includes a Top-Up Facility and is partially underwritten, signaling a strategic push to scale its respiratory monitoring technology.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

EBR Systems has successfully completed a heavily oversubscribed Security Purchase Plan, raising a total of A$75.9 million alongside a prior institutional placement to fund its innovative wireless cardiac pacing technology through 2027.

EMVision Medical Devices has secured a $5 million non-dilutive government grant to accelerate global commercialisation of its innovative First Responder portable brain scanner, aimed at revolutionising pre-hospital stroke and brain injury care.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.